

## **SUPPLEMENTARY MATERIALS**

### **The direct and indirect costs of adult atopic dermatitis**

Janna Manjelienskaia, PhD; Natalie Boytsov, PhD; Matthew A. Brouillette; Uchenna Onyekwere, MD; Evangeline Pierce, PhD; Orin Goldblum, MD; and Machaon Bonafede, PhD

### **Supplementary Table 1: Generic drugs used to identify AD treatments**

<https://www.jmcp.org/pb-assets/SupplmentalMaterial/SupplementaryMaterials21053Table1-1628075434.xlsx>

### **Supplementary Table 2: All-cause and atopic dermatitis (AD)-related direct healthcare costs**

<https://www.jmcp.org/pb-assets/SupplmentalMaterial/SupplementaryMaterials21053Table2-1628075435.xlsx>

### **Supplementary Table 3: Multivariable models of total all-cause direct healthcare costs and all-cause prescription costs of adults with AD and controls**

<https://www.jmcp.org/pb-assets/SupplmentalMaterial/SupplementaryMaterials21053Table3-1628075435.xlsx>

### **Supplementary Table 4: Indirect cost of atopic dermatitis (AD) due to work loss among adult patients in the 2016 and 2017 cohorts**

<https://www.jmcp.org/pb-assets/SupplmentalMaterial/SupplementaryMaterials21053Table4-1628075436.xlsx>